The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts
Open accessAbstract
BACKGROUND & AIMS: Next-generation sequencing (NGS) of pancreatic cyst fluid is a useful adjunct in the assessment of patients with pancreatic cyst. However, previous studies have been retrospective or single institutional experiences. The aim of this study was to prospectively evaluate NGS on a multi-institutional cohort of patients with pancreatic cyst in real time. METHODS: The performance of a 22-gene NGS panel (PancreaSeq) was first retrospectively confirmed and then within a 2-year timeframe, PancreaSeq testing was prospectively used to evaluate endoscopic ultrasound-guided fine-needle aspiration pancreatic cyst fluid from 31 institutions. PancreaSeq results were correlated with endoscopic ultrasound findings, ancillary studies, current pancreatic cyst guidelines, follow-up, and expanded testing (Oncomine) of postoperative specimens. RESULTS: Among 1933 PCs prospectively tested, 1887 (98%) specimens from 1832 patients were satisfactory for PancreaSeq testing. Follow-up was available for 1216 (66%) patients (median, 23 months). Based on 251 (21%) patients with surgical pathology, mitogen-activated protein kinase/GNAS mutations had 90% sensitivity and 100% specificity for a mucinous cyst (positive predictive value [PPV], 100%; negative predictive value [NPV], 77%). On exclusion of low-level variants, the combination of mitogen-activated protein kinase/GNAS and TP53/SMAD4/CTNNB1/mammalian target of rapamycin alterations had 88% sensitivity and 98% specificity for advanced neoplasia (PPV, 97%; NPV, 93%). Inclusion of cytopathologic evaluation to PancreaSeq testing improved the sensitivity to 93% and maintained a high specificity of 95% (PPV, 92%; NPV, 95%). In comparison, other modalities and current pancreatic cyst guidelines, such as the American Gastroenterology Association and International Association of Pancreatology/Fukuoka guidelines, show inferior diagnostic performance. The sensitivities and specificities of VHL and MEN1/loss of heterozygosity alterations were 71% and 100% for serous cystadenomas (PPV, 100%; NPV, 98%), and 68% and 98% for pancreatic neuroendocrine tumors (PPV, 85%; NPV, 95%), respectively. On follow-up, serous cystadenomas with TP53/TERT mutations exhibited interval growth, whereas pancreatic neuroendocrine tumors with loss of heterozygosity of ≥3 genes tended to have distant metastasis. None of the 965 patients who did not undergo surgery developed malignancy. Postoperative Oncomine testing identified mucinous cysts with BRAF fusions and ERBB2 amplification, and advanced neoplasia with CDKN2A alterations. CONCLUSIONS: PancreaSeq was not only sensitive and specific for various pancreatic cyst types and advanced neoplasia arising from mucinous cysts, but also reveals the diversity of genomic alterations seen in pancreatic cysts and their clinical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas
Tanaka, M., Fernández-del Castillo, C., Kamisawa, T., Jang, J. Y., Levy, P., Ohtsuka, T., Salvia, R., Shimizu, Y., Tada, M., & Wolfgang, C. L. (2017) · Pancreatology · doi:10.1016/j.pan.2017.07.007 · Cited by 1,797
Self-citationEuropean evidence-based guidelines on pancreatic cystic neoplasms
The European Study Group on Cystic Tumours of the Pancreas (2018) · Gut · doi:10.1136/gutjnl-2018-316027 · Cited by 1,417
Vege, S. S., Ziring, B., Jain, R., Moayyedi, P., Adams, M. A., Dorn, S. D., Dudley-Brown, S. L., Flamm, S. L., Gellad, Z. F., Gruss, C. B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.015 · Cited by 1,138
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Self-citationWhole-genome landscape of pancreatic neuroendocrine tumours
Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., et al. (2017) · Nature · doi:10.1038/nature21063 · Cited by 999
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841
Self-citationTumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562 · cited 1×
“31,32 Based on diagnostic surgical pathology, BRAF alterations detected within this study correlated with the presence of an IPMN.”
Springer, S., Wang, Y., Dal Molin, M., Masica, D. L., Jiao, Y., Kinde, I., Blackford, A., Raman, S. P., Wolfgang, C. L., Tomita, T., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.041 · Cited by 477 · cited 2×
“11,13,19 In addition, most NGS studies have been focused on the assessment of IPMNs and IPMN-associated PDACs.”
Self-citationScheiman, J. M., Hwang, J. H., & Moayyedi, P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.014 · Cited by 437
Singhi, A. D., McGrath, K., Brand, R. E., Khalid, A., Zeh, H. J., Chennat, J. S., Fasanella, K. E., Papachristou, G. I., Slivka, A., Bartlett, D. L., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313586 · Cited by 405
Self-citationSinghi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348 · cited 1×
“31,32 Based on diagnostic surgical pathology, BRAF alterations detected within this study correlated with the presence of an IPMN.”
Self-citationA multimodality test to guide the management of patients with a pancreatic cyst
Springer, S., Masica, D. L., Dal Molin, M., Douville, C., Thoburn, C. J., Afsari, B., Li, L., Cohen, J. D., Thompson, E., Allen, P. J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4772 · Cited by 217 · cited 1×
“12,13,18 In addition, the combination of VHL alterations and mutations in TP53 or the TERT promoter correlated with an SCA.”
Self-citationPreoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts
Singhi, A. D., Nikiforova, M. N., Fasanella, K. E., McGrath, K. M., Pai, R. K., Ohori, N. P., Bartholow, T. L., Brand, R. E., Chennat, J. S., Lu, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0513 · Cited by 207 · cited 1×
“16 The sensitivity and specificity of a mural nodule can be highly variable and largely attributable to the challenges in differentiating a mural nodule from adherent mucus within the pancreatic cyst by EUS.”
Self-citation
Cited by
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 512
Self-citation
Metadata
- Authors
- Paniccia, A., Polanco, P. M., Boone, B. A., Wald, A. I., McGrath, K., Brand, R. E., Khalid, A., Kubiliun, N., O'Broin-Lennon, A. M., Park, W. G., Klapman, J., Tharian, B., Inamdar, S., Fasanella, K., Nasr, J., Chennat, J., Das, R., DeWitt, J., Easler, J. J., Bick, B., Singh, H., Fairley, K. J., Sarkaria, S., Sawas, T., Skef, W., Slivka, A., Tavakkoli, A., Thakkar, S., Kim, V., Vanderveldt, H. D., Richardson, A., Wallace, M. B., Brahmbhatt, B., Engels, M., Gabbert, C., Dugum, M., El-Dika, S., Bhat, Y., Ramrakhiani, S., Bakis, G., Rolshud, D., Millspaugh, G., Tielleman, T., Schmidt, C., Mansour, J., Marsh, W., Ongchin, M., Centeno, B., Monaco, S. E., Ohori, N. P., Lajara, S., Thompson, E. D., Hruban, R. H., Bell, P. D., Smith, K., Permuth, J. B., Vandenbussche, C., Ernst, W., Grupillo, M., Kaya, C., Hogg, M., He, J., Wolfgang, C. L., Lee, K. K., Zeh, H., Zureikat, A., Nikiforova, M. N., & Singhi, A. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 164
- Issue
- 1
- Pages
- 117-133.e7
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W4302306679
- Cited by
- 203
- References
- 13
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.